Remix Therapeutics
Watertown, US · 5 known investors
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders. The company applies precision medicine approaches across oncology and other therapeutic areas.
AI & Machine LearningBiotech
Founders & leadership
PS
Peter Smith, PhDCo-Founder, President and Chief Executive Officer
PS
Peter SmithCo-Founder, President and Chief Executive Officer
Investors · 5
In the news
- Remix Therapeutics Nasdaq Listing via Passage Bio Mergerallsci.com · 2026
- Remix Therapeutics secures $100M, merges with Passage - Boston Business Journalbizjournals.com · 2026
- Remix Therapeutics to reverse-merge with Passage Bio (PASG) and raise $100Mstocktitan.net · 2026
- Passage Bio to merge with Remix Therapeutics in all-stock deal By Investing.cominvesting.com · 2026
- Sell or Invest in Remix Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · 2025
- Remix Therapeutics raises $70m to develop drugs that reprogram RNA - The Boston Globebostonglobe.com · 2022